Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial

Background. Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a primary immunogen and as a delivery system to treat or prevent a wide range of diseases. Defining the safety and immunogenicity of MVA-BN in key populations is therefore important. Methods. We performed a dose-escalation study...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Walsh, Stephen R., Wilck, Marissa B., Dominguez, David J., Zablowsky, Elise, Bajimaya, Shringkhala, Gagne, Lisa S., Verrill, Kelly A., Kleinjan, Jane A., Patel, Alka, Zhang, Ying, Hill, Heather, Acharyya, Aruna, Fisher, David C., Antin, Joseph H., Seaman, Michael S., Dolin, Raphael, Baden, Lindsey R.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2013
Teme:
Major Articles and Brief Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3654753/
https://ncbi.nlm.nih.gov/pubmed/23482644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jit105
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items